The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 49 | — | 20.1x | Near average | |
Growth | 22 | -100.0% | 5.6% | Below average | |
Quality | 14 | -60.6% | 7.6% | Below average | |
Safety | 64 | 0.7x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Compass Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Compass Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The analyst outlook for CMPX has seen a notable decline over the past 30 days, with the average price target dropping by 7.77% to $10.33 compared to a previous $11.2. This negative adjustment was driven by Raymond James downgrading the stock from 'Outperform' to 'Market Perform', indicating a decline in confidence regarding the stock's ability to achieve exceptional returns in the near term, despite the number of analysts remaining steady at 6.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.